Balanced news tone
News Sentiment
AZTA sentiment intelligence
Azenta Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
51
Balanced news tone
54 relevant articles
News tone and price action are not far from neutral.
75/100 classification confidence.
directly relevant articles
high-authority source matches
-1.9% over one week, +12.3% over four weeks, trend inactive, and below fair value.
Azenta announces completion of B Medical Systems sale to Thelema S.a r.l; Whitestone Group acquires a 40% Stake in Thelema S.a r.l, a Special Purpose Vehicle (SPV) established for the ownership of B Medical Systems
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
75/100 classification
One-week reaction
-1.9%
Price digesting
Trend fit
Trend inactive
12.3% over four weeks
Fair value
-40.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
11
Neutral
36
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
News-Medical
Direct company coverage
Azenta announces completion of B Medical Systems sale to Thelema S.a r.l; Whitestone Group acquires a 40% Stake in Thelema S.a r.l, a Special Purpose Vehicle (SPV) established for the ownership of B Medical Systems
Azenta, Inc. has finalized the sale of B Medical Systems S.á r.l (BMS) to Thelema S.a r.l for $63 million in cash. As part of this transaction, Whitestone Group acquired a 40% stake in BMS through Thelema S.a r.l, investing $19 million. The acquisition aligns with Whitestone Grou
- Tone
- Positive 72/100
- Event
- Deals and strategy
- Published
- 10 Jul 2026 11:10
- Source
- News-Medical
simplywall.st
Direct company coverage
Azenta (AZTA) After The B Medical Sale Is The New Focus Already Priced In
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 13:32
- Source
- simplywall.st
Investing.com Nigeria
Direct company coverage
Azenta completes sale of B Medical Systems for $63 million By Investing.com
Azenta Inc. has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash, a move aimed at focusing on its core life sciences operations. Despite recent disappointing financial results for Q2 2026, analysts predict a return to profitability
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 08 Jul 2026 23:43
- Source
- Investing.com Nigeria
grafa.com
Direct company coverage
Azenta completes $63 million B Medical Systems sale
Azenta (NASDAQ:AZTA) has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million. This transaction, which included a $35 million vendor loan from Azenta, aligns with Azenta's strategy to streamline its portfolio and concentrate on its core life sc
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jul 2026 16:39
- Source
- grafa.com
Moomoo
Direct company coverage
Press Release: Azenta Completes Sale of B Medical Systems
Azenta, Inc. (Nasdaq: AZTA) has announced the completion of the sale of its Brooks Life Sciences (BLS) consumable products and instruments business, B Medical Systems S.à r.l. and its subsidiaries, to B Medical Systems, S.a.r.l. for approximately €145 million in cash. This strate
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 08 Jul 2026 12:39
- Source
- Moomoo
Investing.com
Direct company coverage
Azenta completes sale of B Medical Systems for $63 million
Azenta Inc. has completed the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash, furthering its strategy to focus on core life sciences businesses. The transaction closed on July 1, 2026, and Azenta provided a short-term vendor loan of $35 million
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 08 Jul 2026 12:39
- Source
- Investing.com
TradingView
Direct company coverage
Azenta Finalizes B Medical Divestiture With $35 Million Vendor Loan and Share Pledge
Azenta has finalized the sale of B Medical to Thelema, involving a $35 million vendor loan from Azenta to the buyer. This loan carries 6% interest, a three-month maturity, and is secured by a first-priority pledge over 100% of B Medical's equity. This arrangement facilitates the
- Tone
- Positive 61/100
- Event
- Market update
- Published
- 08 Jul 2026 12:39
- Source
- TradingView
PR Newswire
Direct company coverage
Azenta Completes Sale of B Medical Systems
Azenta, Inc. announced the completion of the sale of its B Medical Systems business to Thelema S.à r.l. for $63 million in cash. This transaction, initially announced in December 2025, closed on July 1, 2026, and is part of Azenta's strategy to focus on its core life sciences bus
- Tone
- Positive 67/100
- Event
- Balance sheet
- Published
- 08 Jul 2026 11:59
- Source
- PR Newswire
Simply Wall Street
Direct company coverage
How Azenta’s Dual Russell 2000 Defensive Index Addition Will Impact Azenta (AZTA) Investors
Azenta, Inc. (NasdaqGS: AZTA) was recently added to both the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, which could increase its visibility among institutional investors. While this inclusion may boost liquidity, it does not fundamentally alter the n
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 06 Jul 2026 16:11
- Source
- Simply Wall Street
The National Law Review
Direct company coverage
Azenta, Inc. (AZTA) Investigation: Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Azenta, Inc. (NASDAQ: AZTA) on behalf of investors. This investigation follows a significant drop in Azenta's stock price after the company reported disappointing Q2 2026 financial results, missing EPS a
- Tone
- Negative 15/100
- Event
- Regulatory and legal
- Published
- 05 Jul 2026 11:12
- Source
- The National Law Review
Finviz
Direct company coverage
AZTA - Azenta Inc Options
This article provides detailed financial data and performance metrics for Azenta Inc. (AZTA), including its stock performance, market capitalization, earnings, sales figures, and various ratios. It also lists insider and institutional ownership, analyst recommendations, and key v
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 02 Jul 2026 20:11
- Source
- Finviz
Moomoo
Direct company coverage
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
This article evaluates Azenta, Inc. (NASDAQ:AZTA) to determine if it presents a current investment opportunity. Given the limited content, a more detailed analysis is not possible.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 21:40
- Source
- Moomoo
Stock Titan
Direct company coverage
AZTA SEC Filings - Azenta Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Azenta Inc. (AZTA) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. Recent filings detail insider transaction amendments, sales related to RSU vesting, and a
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 17:42
- Source
- Stock Titan
Kalkine Media
Direct company coverage
Azenta (NASDAQ:AZTA) Shift Puts Its Defensive Story In Focus
Azenta (NASDAQ:AZTA) is gaining attention after its inclusion in defensive Russell benchmarks, which gives the company a clearer market identity. The company, which provides sample management, storage, and multiomics services for life sciences customers, will need to focus on ser
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 16:39
- Source
- Kalkine Media
TradingView
Direct company coverage
ETFs Investing in Azenta, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Azenta, Inc. It provides a detailed table including each fund's market value, weight of Azenta stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentag
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 13:42
- Source
- TradingView
Simply Wall Street
Direct company coverage
Does Azenta (AZTA) Joining Defensive Russell Indexes Recast Its Role as a Value-Oriented Compounder?
Azenta, Inc. (AZTA) has been included in the Russell 2000 Defensive Index and the Russell 2000 Value-Defensive Index, which may boost its visibility and liquidity. However, this index inclusion does not change the fundamental investment narrative, which remains focused on the exe
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 29 Jun 2026 12:39
- Source
- Simply Wall Street
TradingView
Direct company coverage
Price to sales forward of Azenta, Inc. – NASDAQ:AZTA
This page provides financial information for Azenta, Inc. (NASDAQ: AZTA), specifically focusing on its price to sales forward metric. It also lists various sections available on TradingView related to the company, including financials, news, technicals, and forecasts.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 17:40
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Azenta, Inc. – TRADEGATE:BA3
This article briefly mentions the "Price to earnings forward of Azenta, Inc. – TRADEGATE:BA3" and indicates that the market is closed with no trades. It appears to be a stub or a section from a financial data platform like TradingView, lacking detailed financial analysis or figur
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 06:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Azenta, Inc. – NASDAQ:AZTA
This article provides a financial snapshot focusing on the enterprise value to revenue forward for Azenta, Inc. (NASDAQ: AZTA). It appears to be a stub or an incomplete data point from a financial data platform, indicating the metric for the company. The content includes minimal
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 05:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Azenta, Inc. – TRADEGATE:BA3
The article provides the Enterprise Value to EBITDA forward for Azenta, Inc. (TRADEGATE:BA3). It indicates that the market was closed with no trades at the time of publication. The content also lists various financial tools and community features offered by TradingView.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 04:09
- Source
- TradingView
TradingView
Direct company coverage
Azenta, Inc. Actuals & Estimates (NASDAQ:AZTA)
This article provides an in-depth financial overview of Azenta, Inc. (NASDAQ:AZTA), covering its stock performance, analyst forecasts, historical highs and lows, volatility, market capitalization, and upcoming earnings reports. It details recent earnings surprises, revenue figure
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 07:09
- Source
- TradingView
TradingView
Direct company coverage
Azenta Inc Unsponsored Brazilian Depositary Receipt Repr 0.083333333 Sh Actuals & Estimates (BMFBOVESPA:A2ZT34) — TradingView
This TradingView page provides an overview of Azenta Inc.'s unsponsored Brazilian Depositary Receipt (A2ZT34) on the BMFBOVESPA. It offers access to financial actuals and analyst estimates, including income statement, balance sheet, and cash flow data, allowing users to compare r
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 26 Jun 2026 06:40
- Source
- TradingView
TradingView
Direct company coverage
AZTA Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and analysis for Azenta, Inc. (AZTA) stock, including analyst price targets, past performance, and future earnings estimates. It covers various financial metrics, such as stock price, market capitalization, EBITDA, and revenue, along with
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 05:40
- Source
- TradingView
Sahm
Direct company coverage
The Bull Case For Azenta (AZTA) Could Change Following Profitability Surge And Bullish Signals – Learn Why
Azenta (AZTA) has shown improved financial performance with increased net profit and strong operational efficiency, which could shift its investment narrative. The company's recent profitability surge and bullish technical indicators suggest strengthening investor optimism despit
- Tone
- Positive 71/100
- Event
- Earnings
- Published
- 19 Jun 2026 17:10
- Source
- Sahm
TradingKey
Direct company coverage
Azenta Inc (AZTA) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Azenta Inc (AZTA), noting its current earnings forecast score is 7.43, ranking 291 out of 388 in its industry. Analysts have given an average price target of $41.00, with a "Buy" trend recommendation based on 7 analysts. The expected
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 22:10
- Source
- TradingKey
TradingKey
Direct company coverage
Azenta Inc (AZTA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Azenta Inc (AZTA), listing its major shareholders and their proportional holdings, current as of May 13th. It also provides insights into institutional shareholding trends over several quarters, showing changes in the number of in
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 20:10
- Source
- TradingKey
simplywall.st
Direct company coverage
Assessing Whether Azenta (AZTA) Is Undervalued After Recent Share Price Momentum
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- simplywall.st
Sahm
Direct company coverage
The Bull Case For Azenta (AZTA) Could Change Following Lowered 2026 Outlook And Multiomics Overhaul – Learn Why
Azenta (AZTA) experienced a 3% organic revenue decline in Q2 2026, leading to a lowered full-year guidance for organic revenue and compressed adjusted EBITDA margins. The company is undergoing leadership changes, including a new President for Multiomics, and is integrating UK Bio
- Tone
- Negative 28/100
- Event
- Guidance
- Published
- 07 Jun 2026 15:10
- Source
- Sahm
Investing.com Nigeria
Direct company coverage
Azenta names Trey Martin president of Multiomics business By Investing.com
Azenta, Inc. has appointed Trey Martin as President of its Multiomics business, effective April 6, 2026, to lead the next phase of its multiomics strategy. Martin brings over 30 years of leadership experience in life sciences and previously served as CEO of Maravai Life Sciences
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 07 Jun 2026 00:09
- Source
- Investing.com Nigeria
PR Newswire
Direct company coverage
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Azenta, Inc. - AZTA
Pomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (AZTA) on behalf of investors. This investigation follows Azenta's Q2 fiscal 2026 results, which fell short of expectations, revealing "execution gaps" and a "more cautious demand environment,"
- Tone
- Negative 30/100
- Event
- Regulatory and legal
- Published
- 04 Jun 2026 13:40
- Source
- PR Newswire